|
Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001). |
|
|
Leadership - European Medicines Agency (I); Genomica |
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Incyte; Lilly; Merck Serono; MSD; Novartis; Pfizer; PharmaMar; Roche/Genentech; Sysmex |
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca Spain; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; MSD; Pfizer; Roche |
Other Relationship - Amgen (I); Ipsen (I); Merck (I); Novartis (I); Pfizer (I); Roche; Roche (I); Sanofi (I); SERVIER (I) |
|
|
Consulting or Advisory Role - AstraZeneca; Celgene; Varian Medical Systems |
Research Funding - AstraZeneca (Inst); Varian Medical Systems (Inst); ViewRay (Inst) |
|
|
Honoraria - PeerVoice; Prime Oncology |
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; MedImmune; MSD Oncology; Novartis; Pfizer; Roche |
Research Funding - Abbvie (Inst); AstraZeneca/MedImmune (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
Stock and Other Ownership Interests - Coordination Pharmaceuticals |
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Biolumina; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron |